According to SurgePays's latest financial reports the company has a price-to-book ratio of 1.30.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 3.23 | -79.88% |
2022-12-31 | 16.1 | 134.06% |
2021-12-31 | 6.86 | -592.71% |
2020-12-31 | -1.39 | -78.65% |
2019-12-31 | -6.52 | -61.23% |
2018-12-31 | -16.8 | -84.34% |
2017-12-31 | -107 | 1175.48% |
2016-12-31 | -8.43 | -68.55% |
2015-12-31 | -26.8 | 11360.04% |
2014-12-31 | -0.2338 | 35.98% |
2013-12-31 | -0.1720 | |
2012-12-31 | N/A | |
2011-12-31 | N/A | -100% |
2010-12-31 | -1.15 | -164.47% |
2009-12-31 | 1.78 | -97.36% |
2008-12-31 | 67.4 | |
2007-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.99 | 283.38% | ๐บ๐ธ USA |
Novartis NVS | 5.17 | 296.80% | ๐จ๐ญ Switzerland |
Stryker Corporation SYK | 6.78 | 420.42% | ๐บ๐ธ USA |
Cooper Companies COO | 2.35 | 80.67% | ๐บ๐ธ USA |
STAAR Surgical STAA | 5.08 | 289.89% | ๐บ๐ธ USA |
CONMED CNMD | 2.73 | 109.40% | ๐บ๐ธ USA |
Integra LifeSciences IART | 1.52 | 16.61% | ๐บ๐ธ USA |